AstraZeneca PLC
ZEG
Company Profile
Business description
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
Contact
1 Francis Crick Avenue
Cambridge Biomedical Campus
CambridgeCB2 0AA
GBRT: +44 2037495000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
94,300
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,520.20 | 9.50 | 0.11% |
| CAC 40 | 7,836.79 | 37.04 | -0.47% |
| DAX 40 | 23,527.01 | 111.55 | -0.47% |
| Dow JONES (US) | 42,051.06 | 89.37 | -0.21% |
| FTSE 100 | 8,585.01 | 17.91 | -0.21% |
| HKSE | 23,640.65 | 532.38 | 2.30% |
| NASDAQ | 19,146.81 | 136.72 | 0.72% |
| Nikkei 225 | 38,128.13 | 55.13 | -0.14% |
| NZX 50 Index | 12,793.01 | 13.75 | 0.11% |
| S&P 500 | 5,892.58 | 6.03 | 0.10% |
| S&P/ASX 200 | 8,279.60 | 10.60 | 0.13% |
| SSE Composite Index | 3,403.95 | 29.08 | 0.86% |